医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

HOYA Announces Appointment of Augustine Yee as Executive Officer, Chief Legal Officer and Head of Corporate Development and Affairs

2014年05月22日 PM07:43
このエントリーをはてなブックマークに追加


 

TOKYO

HOYA Corporation (TOKYO: 7741) announced that Augustine Yee has joined the Company as its Executive Officer, Chief Legal Officer and Head of Corporate Development and Affairs.

As the Company’s first Chief Legal Officer and Head of Corporate Development and Affairs, Mr. Yee will be responsible for overseeing the company’s legal affairs, business development and general affairs on a global-scale.

“We are very pleased to have Augustine join us to help shape our future business development and other initiatives,” said Hiroshi Suzuki, Chief Executive Officer of Hoya Corporation. “Augustine brings a great depth of knowledge and experience in business and corporate development in the healthcare industry as well as in the practice of law, all of which will be vital for the company to build value as we achieve sustainable growth.”

“I’m honored to join HOYA Group, a distinctive Japanese company that has a global reputation based on its products and strong technology base, business strategy and operations,” said Mr. Yee. “I’m looking forward to the opportunities and challenges ahead.”

Mr. Yee joined HOYA from AstraZeneca Pharmaceuticals, where he was Head of Asia Pacific Regional and Corporate Business Development. He also previously served as Vice President, Business Development of Archemix Corp, and Vice President, Head of Business and Corporate Development of Prometheus Laboratories and held roles as Senior Vice President of Corporate Development and General Counsel of Deltagen, Inc. Prior to that, he was an attorney practicing corporate security, technology and intellectual property law in American law firms including Pillsbury Madison & Sutro and Lyon & Lyon and was a law clerk to U.S. Federal District Court Judge Edward Rafeedie. Mr. Yee received his law degree magna cum laude from Pepperdine University School of Law and his degree in molecular biology from the University of California at San Diego.

About HOYA

Founded in 1941 in Japan, Hoya is a global med-tech company and a leading supplier of innovative high-tech and medical products. Hoya is active in the fields of Life Care and Information Technology providing eyeglasses, medical endoscopes, intraocular lenses, optical lenses as well as key components for semiconductor devices, LCD panels and HDDs. Hoya currently employs over 35,000 people worldwide. For more information, please visit http://www.hoya.com.

CONTACT

HOYA Corporation
Akiko Chiba, +813-3952-6416
Public Relations
akiko.chiba@hoya.com

同じカテゴリーの記事 

  • ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
  • PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权
  • AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)
  • ReNAgadeセラピューティクス、GanNA Bioと糖鎖生物学に対するコミットメントを継続